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Abstract: Astronauts are at risk of losing 1.0% to 1.5% of their bone mass for every month they
spend in space despite their adherence to diets and exercise regimens designed to protect their
musculoskeletal systems. This loss is the result of microgravity-related impairment of osteocyte
and osteoblast function and the consequent upregulation of osteoclast-mediated bone resorption.
This review describes the ontogeny of osteoclast hematopoietic stem cells and the contributions
macrophage colony stimulating factor, receptor activator of the nuclear factor-kappa B ligand, and the
calcineurin pathways make in osteoclast differentiation and provides details of bone formation,
the osteoclast cytoskeleton, the immune regulation of osteoclasts, and osteoclast mechanotransduction
on Earth, in space, and under conditions of simulated microgravity. The article discusses the need
to better understand how osteoclasts are able to function in zero gravity and reviews current and
prospective therapies that may be used to treat osteoclast-mediated bone disease.
Keywords: osteoclasts; microgravity; spaceflight; osteoblasts; osteocytes; M-CSF; RANKL; bone;
microgravity; cytokines

1. Introduction
The skeletal system of vertebrates has had millions of years to adapt to the force of gravity
on Earth (9.8 m/s2 ) and to allow osteocytes and the immune system to balance the activities of
osteoblasts and osteoclasts. This osteoimmunological system is complex and involves commonly
shared osteoclastogenic factors such as receptor activator of the nuclear factor-kappa B (NF-κB) ligand
and macrophage colony stimulating factor as well as cytokines and immune cells that inhibit or
enhance osteoclast ontogeny [1]. This adaptation has involved the construction of cytoskeletons
supported by actin and intermediate filaments and microtubules [2,3], intracellular adhesion molecules
including integrins and cell extension kinases [4,5], plasma membrane and nuclear mechanosensors [6],
and thermal convection currents which renew nutrients and remove waste [7].
Man’s venture into the vacuum of space where the force of gravity is one millionth of that on Earth
has resulted in adverse effects on the osteoimmunological system, particularly bone homeostasis [8].
Astronauts are not only at risk of progressive bone and cartilage loss while in space but must also face
the reality that space-related bone and joint changes may persist for years after their return to Earth
despite efforts made to protect their skeletal systems [8–13].
In this review, I describe the ontogeny of osteoclast hematopoietic stem cells and the contributions
macrophage colony stimulating factor, receptor activator of NF-κB ligand, and the calcineurin pathways
make in osteoclast differentiation and provide details of bone formation, the osteoclast cytoskeleton,
the immune regulation of osteoclasts, and osteoclast mechanotransduction on Earth, in the microgravity
of space, and in conditions of simulated microgravity. The article discusses the need to better understand
how osteoclasts are able to function in zero gravity and reviews current and prospective therapies that
may be used to treat osteoclast-mediated bone disease.
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bone resorbing osteoclasts. Osteoclast-mediated bone resorption releases osteoblast growth factors
transforming growth factor (TGF)-β, bone morphogenetic proteins (BMPs), and insulin-like growth
factor (IGF)-1 resulting in osteoblast differentiation from mesenchymal stem cells, with subsequent
bone formation and mineralization. Osteoblasts trapped in bone matrix evolve into osteocytes, the most
abundant cells in bone and the primary regulators of bone homeostasis.

osteoblast growth factors transforming growth factor (TGF)-β, bone morphogenetic proteins
(BMPs), and insulin-like growth factor (IGF)-1 resulting in osteoblast differentiation from
mesenchymal stem cells, with subsequent bone formation and mineralization. Osteoblasts trapped
in bone matrix evolve into osteocytes, the most abundant cells in bone and the primary regulators of
bone homeostasis.
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Figure
2. Bone marrow hematopoietic
cells (HSCs)
receptor for
normally present in high concentrations in blood. Circulating CXCR4-expressing HSCs are attracted
sphingosine-1-phosphate (S1PR2) enter the circulation by binding S1P, a chemotactic
to bone surfaces by gradients of stromal-cell-derived factor-1 (SDF-1) (CXCL12) secreted by CXCR4+
RANK+ CD45− stromal marrow cells (colored yellow). HSCs may then be recycled to the bone marrow by
binding S1P to S1PR1 or stay at bone surfaces where they evolve into mature, bone-resorbing osteoclasts
by binding M-CSF and RANKL produced primarily by osteoblasts and osteocytes. OB, osteoblast; RBC,
red blood cell; VEC, vascular endothelial cell.
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5. Osteoclast Differentiation
5.1. M-CSF Pathway
The differentiation of HSCs into osteoclast precursors requires the expression of spleen focus-forming
virus proviral integrin 1 (PU.1), heterodimeric complex of microphthalmia-associated transcription
factor (MITF), and transcription factor E3 (TfE3), which initiate the expression of the colony stimulating
factor-1 receptor (C-Fms) [18]. Ligation of M-CSF to C-Fms initiates the expression of RANK, the cognate
receptor for RANKL. M-CSF ligation also initiates the expression of several cytokines and their receptors
including interleukin (IL)-1α, IL-18, interferon (IFN)-β, IL-11Rα2, IL-6/11R gp130, and IFN-γ-R; also
expressed are factors involved in the cell’s response to RANKL ligation, including tumor necrosis factor
receptor-associated factor 2A (TRAF2A), phosphatidylinositol 3-kinase (PI3K), mitogen-activated
protein kinase kinase kinase 3 (MEKK3), and receptor-interacting serine-threonine kinase 1 (RIPK1) [19].
5.2. RANKL Pathway
Ligation of RANKL to its cognate receptor RANK activates TNF receptor-activating factors
(TRAFs) 1, 2, 3, 5, and 6, adapter proteins that recruit and activate protein kinases. In unstimulated
HSCs, TRAFs 2 and 3, and c baculoviral inhibitor of apoptosis repeat-containing protein 2 (cIAP1) form
a complex that polyubiquitinates NF-κB-inducing kinase (NIK), which is transported to the proteasome
for degradation, resulting in very low levels of NF-κB in unstimulated HSCs [18]. In RANKL-activated
HSCs, polyubiquitination of NIK is inhibited [18], and TRAF6 activates a cascade of kinases, including
extracellular regulated kinase (ERK), p38 mitogen-activated protein kinase (p38), c-jun N-terminal
kinase (JNK), phosphatidylinositol-3 kinase (PI3K), and Akt and IkB kinases [20,21]. This cascade
requires Lys63-linked TRAF-6 auto-ubiquitination [22] and initiates the transcription of activator
protein-1 (AP-1), c-Fos, NF-κB, and nuclear factor of activated T cells cytoplasmic calcineurin-dependent
1 (NFATc1), the master regulator of osteoclast differentiation [20,23,24]. NFATc1 binds to its own
promoter, switching on an epigenetically controlled autoregulatory cycle that permits efficient induction
of the osteoclast-specific genes, tartrate-resistant acid phosphatase (TRAP), cathepsin K, as well as the
fusion-specific genes, dendritic cell-specific transmembrane protein (DC-STAMP) and ATPase H+ transporting
V0 subunit D2 (ATP6v0d2) [20,25,26] (Figure 3).
5.3. Calcineurin Pathway
Membrane-expressed osteoclast-associated receptor (OSCAR) and triggering receptor expressed
in myeloid cells-2 (TREM2) pair with adaptor molecules, Fc receptor common gamma chain (FcRγ)
and DNAX-activating protein 12 kDa (DAP12), to activate immunoreceptor tyrosine-based activation
motif (ITAM). ITAM activates spleen tyrosine kinase (SyK) which, in turn, activates Bruton’s tyrosine
kinase (BtK) and phospholipase C gamma (PLCγ) to induce calcium signaling. This activates cyclic
adenosine monophosphate (cAMP) response element-binding protein (CREB) and the calcineurin
pathway [21,24,25,27], a key costimulatory pathway of NFATc1 [21,23] and an important signaling
component of a number of immune cell receptors [28] (Figures 4 and 5).
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Figure 3. Binding of RANKL to RANK activates TNF receptor activating factors (TRAFs) 1, 2, 3, 5,
TRAF 6 recruits and activates a kinase cascade, which includes extracellular regulated kinase (ERK),
and 6. TRAF 6 recruits and activates a kinase cascade, which includes extracellular regulated kinase
c-jun, N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38), phosphatidylinositol-3
(ERK), c-jun, N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38),
kinase (PI3K), IkB, and AkT. This cascade initiates the transcription of AP-1, c-Fos, NF-κB, and nuclear
phosphatidylinositol-3 kinase (PI3K), IkB, and AkT. This cascade initiates the transcription of AP-1,
factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1), with consequent induction
c-Fos, NF-κB, and nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1),
of the osteoclast specific genes, TRAP, cathepsin K, DC-STAMP, and ATP6v0d2. C-IAP1/2, cellular
with consequent induction of the osteoclast specific genes, TRAP, cathepsin K, DC-STAMP, and
amino-terminal inhibitor of apoptosis 1 and cellular amino-terminal inhibitor of apoptosis 2; AKT,
ATP6v0d2.
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5.3. Calcineurin Pathway
Membrane-expressed osteoclast-associated receptor (OSCAR) and triggering receptor
expressed in myeloid cells-2 (TREM2) pair with adaptor molecules, Fc receptor common gamma
chain (FcRγ) and DNAX-activating protein 12 kDa (DAP12), to activate immunoreceptor
tyrosine-based activation motif (ITAM). ITAM activates spleen tyrosine kinase (SyK) which, in turn,
activates Bruton’s tyrosine kinase (BtK) and phospholipase C gamma (PLCγ) to induce calcium
signaling. This activates cyclic adenosine monophosphate (cAMP) response element-binding protein
(CREB) and the calcineurin pathway [21,24,25,27], a key costimulatory pathway of NFATc1 [21,23]
and an important signaling component of a number of immune cell receptors [28] (Figures 4 and 5).

Figure 4. Membrane expressed osteoclast-associated receptor (OSCAR) and triggering receptor
Figure 4. Membrane expressed osteoclast-associated receptor (OSCAR) and triggering receptor
expressed in myeloid cells-2 (TREM2) pair with adaptor molecules, Fc receptor common gamma chain
expressed in myeloid cells-2 (TREM2) pair with adaptor molecules, Fc receptor common gamma
(FcRγ) and DNAX-activating protein 12 k-DA (DAP12) to activate immunoreceptor tyrosine-based
chain (FcRγ) and DNAX-activating protein 12 k-DA (DAP12) to activate immunoreceptor
activation motif (ITAM). ITAM activates spleen tyrosine kinase (SyK), Burton’s tyrosine kinase (BtK),
tyrosine-based activation motif (ITAM). ITAM activates spleen tyrosine kinase (SyK), Burton’s
and phospholipase C gamma (PLCγ) to induce calcium signaling which is required to activate cAMP
tyrosine kinase (BtK), and phospholipase C gamma (PLCγ) to induce calcium signaling which is
response element-binding protein (CREB) and the calcineurin pathway, a key costimulatory pathway
required to activate cAMP response element-binding protein (CREB) and the calcineurin pathway, a
of NFATc1 and an important signaling component of a number of immune cell receptors.
key costimulatory pathway of NFATc1 and an important signaling component of a number of
immune cell receptors.

chain (FcRγ) and DNAX-activating protein 12 k-DA (DAP12) to activate immunoreceptor
tyrosine-based activation motif (ITAM). ITAM activates spleen tyrosine kinase (SyK), Burton’s
tyrosine kinase (BtK), and phospholipase C gamma (PLCγ) to induce calcium signaling which is
required to activate cAMP response element-binding protein (CREB) and the calcineurin pathway, a
key costimulatory pathway of NFATc1 and an important signaling component of a number of
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to C-Fms results in the expression of transcription factors activator protein 1 (AP-1), NF-κB, NFATc1,
the receptor for RANKL. Binding of M-CSF and RANKL to their cognate receptors promotes further
differentiation into osteoclast precursors expressing transcription factors NF-κB, NFATc1, and dendritic
cell-specific transmembrane protein (DC-STAMP). These cells fuse, forming mature TRAP-, cathepsin
K-positive osteoclasts.

6. Osteoclast Cytoskeleton
6.1. Cytoskeleton Elements
The osteoclast cytoskeleton is made of filamentous structures that belong to one of four
categories: polarized actin filaments; polarized microtubules; non-polarized intermediate filaments;
or non-polarized septin filaments. The cytoskeleton fulfills essential functions including cell adhesion,
migration, contractility, division, vesicular transport, and bone resorption [2–6].
6.1.1. The Sealing Zone
Osteoclasts adhere to bone by means of the sealing zone, a belt of densely packed microtubulestabilized podosomes (Figure 6). Podosomes mediate adhesion via integrin αvβ3, the major osteoclast
integrin. In the center of the sealing zone, the osteoclast membrane differentiates into a ruffled border,
where it secretes hydrochloric acid and proteases (cathepsin-K, MMP9, and MMP14) to dissolve
hydroxyapatite crystals and bone matrix, respectively [2].
6.1.2. The Actin Cytoskeleton
The core domain of podosomes consists of branched actin that polymerizes below the plasma
membrane. The core is surrounded by unbranched actinomysin filaments, which connect to integrins
and link neighboring podosomes. The core also contains adhesion protein CD44. Although the typical
half-life of a podosomes is measured in minutes, the podosome belt is made of thousands of podosomes
and can last for hours [2].

Osteoclasts adhere to bone by means of the sealing zone, a belt of densely packed
microtubule-stabilized podosomes (Figure 6). Podosomes mediate adhesion via integrin αvβ3, the
major osteoclast integrin. In the center of the sealing zone, the osteoclast membrane differentiates
into a ruffled border, where it secretes hydrochloric acid and proteases (cathepsin-K, MMP9, and
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and integrins, and has been proposed to crosslink actin cytoskeleton and microtubules in osteoclasts [2].
The tyrosine kinase, Src, is a key controller of podosome dynamics and organization. Src binds
6.1.4.
Intermediate
and Septin
Filaments
to tyrosine
kinase Pyk2
resulting
in their activation and regulation of podosome dynamics largely
through small GTPases of the Rho family [2].
Intermediate filaments include vimentin, plectin, and fimbrin; they connect the nuclear and plasma
membranes with microtubules and actin filaments. Vimentin filaments are found along microtubules
and the podosomal belt, and plectin and fimbrin are both podosomal proteins. Plectin is required for
microtubule acetylation and Src and Pyk2 activities, and, along with fimbrin, connects vimentin to
actin filaments [2].
Relatively little is known about the functions of the 13 septin filaments. Septin 9 links septin
filaments to other cytoskeletal elements and membranes, bundles microtubules, and inhibits the activity
of myosin and cofilin. It is associated with actin filaments and microtubules in the sealing zone, and its
inhibition is detrimental to bone resorption [2].
7. Immunoregulation
7.1. Cytokines
Osteoclasts are immunologically reactive cells that have taken over the duties of balancing bone
resorption with bone formation. As such, they are responsive to a variety of pro-inflammatory cytokines,
which generally increase their resorptive capacity, and anti-inflammatory cytokines, which generally
diminish their ability to resorb bone. These interactions play a critical role in inflammatory bone and
joint diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and osteoarthritis,
particularly post-traumatic osteoarthritis. The following lists cytokines based on whether their
predominant effect on osteoclastogenesis is favorable or inhibitory.
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7.1.1. Osteoclastogenic Cytokines
Foremost among the osteoclastogenic cytokines is TNF-α, a potent stimulator of osteoclastogenesis
and a dominant cytokine in most bone and joint inflammatory diseases including post-traumatic
osteoarthritis. In this regard, it is important to note that astronauts experience traumatic joint injuries
involving their knees, ankles, hips, and shoulders at almost three times the rate as individuals on Earth.
TNF-α induces osteoclastogenesis in RANKL- and M-CSF-positive hematopoietic cell
precursors [29,30], where its effects are mediated by TNF-α receptors type 1 (p55r) and type 2 (p75r),
the former being the most effective in inducing the differentiation of TRAP-positive multinucleated
cells [31]. In addition, TNF-α has the capacity to inhibit osteoblastogenesis by downregulating the
expression of IGF-1 in mesenchymal stem cell precursors [32].
Also prominent among the osteoclastogenic cytokines are IL-1α and IL-1β. Tanabe and associates
examined the effect of IL-1α on cultures of rat osteoblasts and hematopoietic stem cells and found that it
stimulated osteoclastogenesis by upregulating M-CSF and prostaglandin E2 (PGE2) production and by
decreasing OPG production in osteoblasts [33]. Azuma and associates found that IL-1β enhanced the
ability of TNF-α to upregulate bone resorption by TRAP-positive multinucleated cells [31]. However,
IL-1β has also been reported to suppress osteoclast formation by upregulating OPG production by
chondrocytes [34].
Transforming growth factor-β, which is released from the bone matrix during bone resorption,
has been shown to enhance osteoclast differentiation in RANKL- and M-CSF-stimulated HSC
cultures [35]. Bone morphogenetic protein-1 in conjunction with RANKL has been shown to increase the
differentiation and survival of osteoclasts [36]. Moreover, IL-7 + RANKL produced by activated T cells
is reported to stimulate osteoclastogenesis in cultures of peripheral blood mononuclear cells [37]. IL-34
produced by osteoblasts recognizes the receptor for M-CSF (C-Fms) on osteoclast progenitors, thereby
promoting osteoclastogenesis [38]. In association with inflammatory joint diseases such as rheumatoid
arthritis, IL-17 produced by T17 lymphocytes serves as a potent osteoclastogenic cytokine [1].
7.1.2. Anti-Osteoclastogenic Cytokines
Foremost among the anti-osteoclastogenic cytokines are IL-4 and IL-10. Mohamed and associates
found that low doses of IL-4 inhibited RANKL-induced osteoclastogenesis in monocytes/macrophages
and in bone marrow osteoclast precursors by downregulating NFATc1 mRNA expression [39].
In keeping with these findings, Wei and associates found that IL-4 inhibited osteoclastogenesis
by blocking the JNK, p38, and ERK protein kinase pathways, which are upstream of NFATc1 [40].
In their study on the effect of IL-4 on TNF-α-mediated osteoclast formation in live murine calvariae,
Fujii and associates found that IL-4 also inhibited RANKL expression in TNF-α-activated stromal
cells [41]. Furthermore, Zhao and Ivashkiv reported that IL-4 limits bone resorption by promoting
OPG expression and suppressing the expression of RANKL, RANK, NF-κB, c-Fos, NFATc1, MAPK,
and calcium signaling during osteoclast formation [42]. Using a RAW267.4 macrophage cell line and
murine bone marrow cells, Mohamed and associates reported that IL-10 inhibited osteoclastogenesis
by downregulating RANKL-induced expression of c-Fos and its downstream target, NFATc1 [43].
Additionally, Zhao and Ivashkiv reported that IL-10 limits osteoclast formation by inhibiting the
expression of c-Fos, c-Jun, TREM2, and NFATc1 in osteoclast precursors [42].
IL-6, IL-12, IL-18, and interferon (IFN)-γ also possess anti-osteoclastogenic properties. Honda
studied cultures of chondrocytes containing IL-6 and its soluble receptor, sIL-6r, for up to 28 days;
he then tested the culture supernatant for its ability to induce differentiation of RAW264.7 cells into
osteoclast precursors. He found that IL-6 and IL-6r suppressed the differentiation of osteoclasts by
inducing chondrocytic PGE2 [44]. Using mouse bone marrow cultures, Kitaura and associates found
that IL-12 when added to TNF-α-stimulated cultures induced osteoclast apoptosis by upregulating
their expression of Fas/Fas ligands [45]. Using injections of TNF-α alone and with IL-18 or IL-18 + IL-12
into live murine supracalvaria, Morita and associates found that IL-12 enhanced IL-18s ability
to inhibit TNF-α-mediated osteoclastogenesis and that the inhibition was T-cell independent [46].
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Horwood and associates also reported that IL-12 inhibited osteoclast formation in vitro [47]. Using
co-cultures of osteoblasts and hematopoietic cells, Udagawa and associates found that IL-18 inhibited
osteoclastogenesis by downregulating osteoblast production of M-CSF [48]. Moreover, using cultures
of murine bone marrow macrophages, Kohara and associates found that IFN-γ directly inhibited
TNF-α-mediated osteoclastogenesis and induced osteoclast precursor apoptosis by upregulating
Fas/Fas ligand binding [49] (Table 1).
Table 1. Effect of anti-osteoclastogenic cytokines on hematopoietic stem cells.
Cytokine

M-CSF/RANKL
Pathways

Calcineurin
Pathway

IL-4

Blocks JNK, P38, ERK
protein kinase signaling.
Inhibits NF-κB, c-Fos,
NFATc1 transcription

↓ calcium
signaling

IL-6 sIL-6R

PGE2-mediated ↓
osteoclastogenesis

IL-10

Inhibits c-Fos, c-Jun,
NFATc1 transcription

IL-12

↑ IL-18 inhibition of
TNF-α-mediated
osteoclastogenesis

IL-18

↓ osteoblast M-CSF
production. Inhibits
TNF-α-mediated
osteoclastogenesis

IFN-γ

Inhibits TNF-α-mediated
osteoclastogenesis

Apoptotic
Pathway

RANK/RANKL/OPG
Expression

References

↓ RANK, RANKL
expression ↑ osteoblast
OPG expression

[39–42]

[44]
Inhibits TREM2
expression

[43]
↑ Fas/Fas
ligand
expression

[45,47]

[46,47]

↑ Fas/Fas
ligand binding

[49]

IL, interleukin; IFN, interferon; PGE2, prostaglandin E2; TNF, tumor necrosis factor; OPG, osteoprotegerin.

8. Mechanotransduction
Cellular responses to external forces are mediated by actin, microfilaments, and microtubules of the
cytoskeleton, by integrins and other intracellular adhesion molecules, and by membrane and nuclear
mechanosensors. Cell extension kinases, gravisensing organelles, and thermal convection currents
that enable heat and nutrient exchange and removal of waste are also involved [1–7]. In addition to
the force of gravity, mechanotransduction in bone is mediated by fluid shear stresses [50], hydrostatic
pressures [51], and the force of muscular contraction [52].
Osteoclast responses to mechanical loading are mediated largely by osteoblasts and osteocytes.
Osteoblasts inhibit osteoclastogenesis by reducing the available amounts of RANKL by producing
OPG, a decoy receptor for RANKL. Osteocytes control osteoclast activity by secreting sclerostin,
which increases bone resorption by downregulating osteoblast OPG production and decreases
osteoblastogenesis by inhibiting Wnt/β-catenin signaling pathways in osteoblast precursors [53].
8.1. Mechanotransduction in Space (10−6 g)
The force of gravity in space is one millionth of that experienced on Earth (9.8 m/s2 ). In stark
contrast to the devastating effects of microgravity on osteoblasts, whose cytoskeletons may implode do
to the failure of microtubules and actin filaments [54,55], and osteocytes, which undergo apoptosis as
early as three days into space flight [56], osteoclasts maintain their ability to resorb bone in microgravity.
Along with the diminished force of muscular contraction on bone, these changes account for the
space-related loss of bone mass. Furthermore, the detrimental effects of space travel on bone and
cartilage can persist for years after astronauts return to Earth.
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8.1.1. Studies Using Live Animals
Early studies on the effects of spaceflight on bone homeostasis were reported by Vico and associates.
In one study, they flew seven Wistar rats for seven days aboard BIOCOSMOS 1667 and performed
histomorphometric studies on the tibias, femurs, and thoracic and lumbar vertebrae of the sacrificed
animals. Microgravity reduced tibial trabecular bone volume by 47–55%, trabecular thickness by
20–24%, and trabecular density by 40–43% as compared to ground controls. In contrast, femoral
trabecular bone at the site of muscular insertions and vertebral bone showed no significant changes
when compared to ground controls. The authors were unable to explain the different outcomes for
the weight-bearing bone models [57]. Using similar methods, the same investigators had previously
shown that 5 days of spaceflight aboard the COSMOS 1514 biologic satellite increased the number of
TRAP-positive osteoclasts per mm2 of thoracic and lumbar vertebrae [58] and that 14 days of flight
aboard the COSMOS 2044 space shuttle increased the osteoclast number and resorptive activity in the
male Wistar rat tibial metaphysis [59].
Blaber and associates analyzed the pelvic and femoral bones of eight C57BL/6 mice flown for
15 days on the STS-131 space shuttle mission using nano-CT scans and measurements of TRAP. They
found that microgravity reduced the bone volume by 6.3% and bone thickness by 11.9% and increased
the number of bone-surface TRAP-positive osteoclasts by 170% compared to that of ground controls,
indicating enhanced osteoclast-mediated bone resorption. They also documented osteocyte apoptosis
as reflected by increases in lacunar and canalicular diameters [60].
Chatani and associates used medaka fish and medaka fish larvae to study osteoclast function
during two flights aboard the International Space Shuttle. They used double transgenic fish with a TRAP
promoter linked to a green fluorescent protein and a metalloproteinase 9 (MMP9) promoter linked to a
red fluorescent protein to identify osteoclasts. The fish were studied in vivo using a remote-controlled
microscope on board the Space Shuttle; RNA was extracted from several fish on days 4 and 6 of
spaceflight for subsequent transcriptome analysis. They found that in vivo signals of osteoclast activity
were upregulated at days 4 and 6 after launch, and that expression of osteoclast-specific genes TRAP,
cathepsin K, and MMP9 were upregulated on day two of the flight [61].
8.1.2. Studies Using Cell Cultures
Nabavi and associates measured the effects of 5 days of spaceflight on cultures of mouse calvaria
osteoblasts and osteoclasts derived from RANKL-stimulated RAW 264.7 murine macrophage cell
lines. To measure their resorptive capacity, osteoclasts were subcultured on Osteologic CC2 slides
and Narwal ivory slices prior to flight. On return from space, osteoblasts were immunostained with
monoclonal antibodies to α-tubulin, acetylated tubulin, vinculin, paxillin, zyxin, and tubulin and
examined by fluorescent microscopy. The authors found that spaceflight osteoblasts had shorter
and curvier microtubules, a reduced number and size of focal adhesins, and more condensed and
fragmented nuclei when compared to ground controls, findings in keeping with other reports on the
adverse effects of microgravity osteoblast cytoskeleton integrity. In contrast, on analyzing approximately
16,000 resorptive pits on Osteologic slides, they found that microgravity increased the resorptive activity
of osteoclasts when compared to that of ground controls, underscoring the resilience of these cells to the
effects of zero gravity [54].
Tamma and associates flew bioreactor cultures of osteoclasts and their precursors for 10 days on the
FOTON-M3 mission. Osteoclast precursors were cultured on skelite (a 3-dimensional bone-like material)
or devitalized bovine bone. They found that microgravity increased by several-fold the expression of
genes involved in osteoclast activation and function; osteoclast bone resorption was also increased as
evidenced by increases in collagen telopeptide production as compared to that of ground controls [62].
8.1.3. Summary
Both live animal and cell culture studies are uniform in documenting an upregulation of osteoclast
numbers, resorptive activity, and resorption-related gene expression in the microgravity of space
(bone volumes, masses) (Figure 7).
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Aguirre and associates subjected Swiss Webster mice to 1–18 days of 30 head-down tail suspension
Aguirre and associates subjected Swiss Webster mice to 1–18 days of 30° head-down tail
and performed histomorphometric, bone density DXA analysis, and bone compression resistance
suspension and performed histomorphometric, bone density DXA analysis, and bone compression
studies on lumbar vertebrae at various time intervals. They found evidence of osteocyte apoptosis
resistance studies on lumbar vertebrae at various time intervals. They found evidence of osteocyte
on day 3 of suspension followed by increased endosteal levels of osteoclast numbers and resorptive
apoptosis on day 3 of suspension followed by increased endosteal levels of osteoclast numbers and
activity and decreased bone density and compressive resistance at 18 days of tail suspension. They
resorptive activity and decreased bone density and compressive resistance at 18 days of tail
concluded that simulated gravity causes osteocyte apoptosis and consequent increases in levels of
osteoclasts and osteoclast-mediated bone resorption [64] (Figure 7).
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8.2.2. Studies Using Cell Cultures
Rucci and associates studied the effect of simulated microgravity on osteoclastogenesis and
bone resorption using 7-day-old CD1 mice calvariae cells for osteoblast cultures and CD1 mouse
long bone marrow cells for osteoclast cultures. Cultures were done using NASA’s Rotating Wall
Vessel Bioreactors. Osteoblasts were cultured for 24 h and analyzed for the expression of alkaline
phosphatase (Alp), runt-related transcription factor-1 (Runx2), parathyroid hormone (PTH)/PTH
peptide (P) receptor, and type I collagen and osteocalcin (OCN); osteoblast culture supernatants were
assayed for osteoprotegerin (OPG) and RANKL concentrations and used as media for osteoclast
cultures. Osteoclasts were cultured for 7 days on bone slicers and in the osteoblast culture media,
stained for TRAP, and assayed for resorptive activity by measuring the number of bone slice resorption
pits. The investigators found that simulated microgravity enhanced osteoclastogenesis by decreasing
osteoblast production of OPG (increasing RANKL/OPG ratios) [65].
Using NASA’s Rotary Wall Vessel Bioreactor (RWV) and rotary cell cultures of RAW 264.7
osteoclast progenitor cells, Sambandam and associates found that simulated microgravity increased
osteoclastogenesis by twofold and upregulated the production/expression of factors involved in
osteoclastogenesis, including cytokines, growth factors, proteases, signaling proteins, and transcription
factors c-Jun, MITF, and CREB as compared to ground controls [66] (Table 2).
Table 2. Effect of microgravity on osteoclast hematopoietic stem cell precursors.
Cell

M-CSF/RANKL Pathways

Calcineurin Pathway

Sclerostin Pathway *

HSC

↑ c-Jun, MITF, CREB [63], TRAIL,
TRAF-6, OC-STAMP,
DC-STAMP [64], syncytin-A [60]

↑ S100AB protein and
cytosolic calcium [63]

↑ osteoclastogenesis secondary
to ↓ OPG production [53]

* Microgravity-related osteocyte apoptosis increase their secretion of sclerostin [60]. TRAIL, tumor necrosis
factor-related apoptosis-inducing ligand.

Using the same culture system, Sambandam and associates studied the effects of simulated
microgravity on osteoclast precursor autophagy. RAW 264.7 osteoclast precursors cells were cultured
for 24 h, and their RNA was extracted and analyzed for the expression of autophagic genes. In addition,
marrow cells extracted from the long bones of C57BL/6 mice were cultured for 7 days with added
RANKL and M-CSF ± the autophagic inhibitor, 3-methyladenine (3-MA). They found that microgravity
increased the expression of autophagic genes and produced multiple autophagosomes in RAW 264.7
cultures. They also found that 3-MA inhibition of autophagy in the RANKL/CSF+ marrow cultures
inhibited osteoclastogenesis. They concluded that “autophagy plays an important role in enhanced
osteoclast differentiation and could be a potential therapeutic target to prevent bone loss in astronauts
during space flight missions” [67].
In a separate study using the same culture system and 24-h cultures of RAW 264.7 osteoclast
precursors, Sambandam et. al. found that the expression of tumor necrosis factor-related apoptosisinducing ligand (TRAIL), TRAF-6, and the fusion genes OC-STAMP and DC-STAMP were upregulated
in simulated microgravity and concluded that “inhibition of TRAIL expression could be an effective
countermeasure for µXg-induced bone loss” [68].
Using the RWV, Ethiraj and associates cultured bone marrow cells flushed from the long bones of
6–8-week-old C57BL/6 mice for 24 h, and then subcultured the cells for 7 days with added RANKL
and M-CSF ± a syncytin-A knockdown small-interfering RNA (siRNA) and stained the cells for
TRAP and syncytin-A. They found that inhibition of syncytin-A decreased microgravity-induced
osteoclastogenesis. They concluded that increased syncytin-A production in simulated microgravity
upregulated osteoclastogenesis and that “targeting syncytin-A expression may be an effective
countermeasure to control bone loss under microgravity conditions” [69] (Table 2, Figure 7).
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9. Discussion
Unloading of bone on Earth and in the microgravity of space is associated with decreased bone
formation and increased bone resorption. The reasons are complex but include the reduction of
bone-loading signals normally transduced by shear stresses and hydraulic pressures exerted on
osteocytes residing in the lacunar–canalicular network of bone, the increased secretion of sclerostin
by pre-apoptotic osteocytes, and microgravity-induced disruption of osteoblast nuclei, cytoskeleton,
and intracellular adhesins.
Experiments have been consistent in showing that conditions of microgravity and simulated
microgravity decrease the mineral content and cortical and trabecular microstructures of bone,
increase osteoclast secretion of sclerostin, decrease osteoblastogenesis and osteoblast secretion of OPG,
and increase osteoclast differentiation, fusion, and expression of regulatory and osteoclast-specific
genes [57–69]. However, why, in contrast, to osteocytes and osteoblasts, do osteoclasts with their
complex cytoskeletons, remain functional under conditions of bone unloading—both on Earth and
in space? How is the integrity of the sealing zone, so essential for bone resorption, maintained
under such adverse conditions? What happens to the complex associations of actin and intermediate
filaments, septins, and microtubules in osteoclasts subjected to microgravity? Why are M-CSF, RANKL,
and calcineurin transcriptional pathways upregulated in osteoclast hematopoietic stems cells but
downregulated in osteoblast mesenchymal stem cell precursors in zero gravity? Moreover, is there any
relation between osteoclast survival and space-related changes in osteoclast regulation by immune
cells and their cytokines? These intriguing questions should provide an ample basis for future research
into the amazingly resilient osteoclast, including the development of agents capable of disabling key
elements in its cytoskeleton.
In addition to bone unloading, a number of physiopathological conditions are characterized by
excessive osteoclast activity. These include but are not limited to menopause, juvenile Paget’s disease
of bone, inflammatory joint diseases, bone cancers such as multiple myeloma, and glucocorticoid
therapy [1,2]. Thus, it is not surprising that many of the studies on bone homeostasis have been
motivated by the need to find treatments capable of modifying osteoclast activity without inducing
osteopetrosis [8]. I have listed below several potential treatments designed for this purpose.
9.1. Biphosphonates
Bisphosphonates have long been used with success to control osteoclast-mediated bone disease;
these agents are incorporated into the bone matrix and are ingested by bone-resorbing osteoclasts,
causing their apoptosis. However, biphosphonates inhibit the stimulatory activity of osteoclasts on
osteoblast differentiation and, as a consequence, patients on these drugs suffer from a blockade of
de novo bone formation [12,70].
9.2. Anti-RANKL Antibody
A recently developed human monoclonal antibody against RANKL, denosumab, has been shown
to have undesirable side effects and, similar to biphosphonates, adversely affects osteoblastogenesis [71].
9.3. Cathepsin K Inhibitor
An inhibitor of cathepsin K, odanacatib, was shown to prevent pathological bone loss while
preserving bone formation but failed in clinical phase III trials due to increased risk of stroke [72].
9.4. Anti-Sclerostin Antibody
Scientists have developed a humanized monoclonal antibody directed against sclerostin
(romosozumab), which is approved for the treatment of osteoporosis. Clinical trials have shown that
monthly subcutaneous injections of romosozumab are effective in increasing bone formation and
density and decreasing bone resorption—results in keeping with the known effects of sclerostin on bone
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homeostasis [73]. However, there is some concern about the potential cardiotoxicity of romosozumab,
prompting the need for further observations [74]. In addition, there is evidence in experimental animals
that sclerostin generated in response to TNF-α and IL-1β improves post-traumatic osteoarthritis by
inhibiting the activity of proteolytic enzymes involved in cartilage degradation [75]. Because astronauts
experience an increased incidence of post-traumatic osteoarthritis involving their knees, ankles, hips,
and shoulders, their use of anti-sclerostin antibody during spaceflight may prove to be a double-edge
sword. It is important to note that both TNF-α and IL-1β play an important role in the pathophysiology
of osteoarthritis [76].
9.5. Osteoprotegerin
Osteoprotegerin-Fc given subcutaneously to mice flown for 12 days in space produced a sustained
suppression of bone resorption and, thus, deserves further study [77].
9.6. Melatonin
Ikegame and associates reported that melatonin, a well-tolerated and widely available compound,
stimulated calcitonin mRNA expression and decreased RANKL mRNA expression in cultured fish
scales (a surrogate for bone cultures) during an 11-day space flight aboard the International Space
Shuttle. Calcitonin is an osteoclast-inhibiting hormone, and, as previously noted, RANKL binding to
RANK is required for osteoclastogenesis. The authors posited that melatonin might prove useful in
preventing space-related bone loss and, thus, deserves further evaluation [78].
9.7. Insulin-Like Growth Factor-1
Insulin-like growth factor (IGF)-1, which plays a major role in all phases of bone and cartilage
growth, has been shown to increase rodent humerus periosteal bone formation by 37% during a 10 day
Space Shuttle flight [8]. The potential of IGF-1 and other growth factors such as TGF-β and BMP to
regulate bone homeostasis in situations of bone unloading merits further investigation.
10. Future Prospects
China, Russia, and the United States have plans to establish colonies on our moon sometime
in the 2030s and to use the moon as a way station for eventual trips to Mars. These plans include
lunar-orbiting space stations. Thus, it would seem that the future holds ample opportunities to study
the effects of varying degrees of microgravity on the remarkable and resilient osteoclast.
11. Conclusions
Astronauts are at risk of losing bone mass and damaging joint cartilages despite NASA’s efforts
to protect their skeletal system by initiating exercise programs and nutritious diets. Bone loss is
the consequence of microgravity-related impairment of osteocyte and osteoblast function and the
consequent upregulation of osteoclast-mediated bone resorption. Further research is needed to
better understand how osteoclasts are able to function in zero gravity and to develop more effective
interventions to prevent osteoclast-mediated bone disease.
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